Sponsors (6)
Introduced February 27, 2025 by Marilyn Strickland · Last progress February 27, 2025
The bill directs significant federal effort—research funding, workforce incentives, coordinated planning, and outreach—to reduce rare-disease disparities for minority and tribal communities, but it raises federal costs, implementation and privacy risks, and may redirect limited research resources while many benefits depend on future funding and agency action.
Racial and ethnic minority and tribal patients will get more targeted research, screening, diagnosis, and treatment efforts for rare diseases through new grants, programs, and disease identification activities.
Policymakers, agencies, and researchers will have stronger interagency coordination, plans, and regular reporting (NIH/CDC/FDA/HHS) to identify disparities and translate findings into policy and programs.
Students, clinicians, and underserved communities will gain new training, scholarships, loan-repayment, mentoring, and internship programs that expand the rare-disease clinical and research workforce and encourage service in high-need areas.
Taxpayers will face increased federal spending to fund new grants, scholarships, reports, and programs, potentially requiring appropriations or trade-offs elsewhere in the budget.
Racial and ethnic minority and tribal individuals risk exposure of sensitive health and genetic data unless strong privacy, consent, and data-governance safeguards are enforced.
Smaller tribal clinics, community providers, some grantees, and federal agencies may face substantial administrative and compliance burdens to apply for, manage, and report on new grants and mandated plans, potentially diverting staff time from services or other programs.
Based on analysis of 11 sections of legislative text.
Authorizes coordinated research, grants, workforce programs, data collection, and reports to address rare diseases and health disparities affecting minority and Tribal populations.
Creates a coordinated federal effort to improve research, data, clinical care, workforce training, and public awareness for rare diseases that disproportionately affect minority and Tribal communities. It authorizes new grants and programs for Tribal epidemiology centers, NIH and CDC research coordination and planning, HRSA training and loan-repayment/scholarship programs, public education, and surveys of Medicare and FDA policies to identify barriers and gaps. Requires multiple reports and plans to Congress and deadlines for agency reviews (e.g., 180 days, 1 year, 2 years). The bill mainly authorizes grant programs and planning activities across HHS agencies; it does not itself appropriate funds and would rely on future appropriations to implement most new programs.